fbpx
Connect with us

News

Device slashes heart failure hospitalisation and readmittance

Published

on

Heart

A medtech innovation showed significant reductions in heart failure hospitalisations and 30-day hospital readmittance rates in a newly-published study.

The analysis, conducted by investigators at Abington Hospital-Jefferson Health, Pennsylvania, also found improvements in renal function response from the Nuwellis Aquadex FlexFlow System.

The 10-year, real-world retrospective analysis included 334 hospitalised acute decompensated heart failure patients with fluid overload treated with adjustable ultrafiltration (UF) using Aquadex ultrafiltration.

Findings from the study included:

  • Patients experienced an overall 81 per cent decrease in heart failure hospitalisations per year;
  • Rehospitalisations for patients after receiving UF with Aquadex were 48 per cent less than the national average at 30 days (12.4 per cent vs. 24 per cent);
  • 55 per cent of patients achieved sustained weight loss greater than 15 lbs.; and
  • All patients had stable renal function at follow-up.

Donald Haas, MD, Medical Director, Mechanical Circulatory Support and Director, Comprehensive Heart Failure Program at Abington-Jefferson Health, and Co-Investigator, said:

“We found that ultrafiltration can be used safely and effectively for significant volume removal among patients admitted with decompensated heart failure.

“Compared to previous trials with ultrafiltration, this real-world experience demonstrates that ultrafiltration compares favourably for weight/volume loss and renal function response, and this may be associated with a lower heart failure rehospitalisation rate.”

Nestor Jaramillo, Jr., President and CEO of Nuwellis, said:

“These results are consistent with the AVOID-HF Win Ratio analysis […] that demonstrated statistically significant clinical superiority of ultrafiltration therapy using the Aquadex System over diuretics in reducing heart failure events within 30 and 90 days.

“Nuwellis is committed to making Aquadex therapy the standard of care for fluid management in heart failure patients that are unresponsive to diuretics.”

Fluid overload is a common symptom of heart failure, usually treated with diuretics.

The condition occurs when the heart fails to pump enough blood for the kidneys to function properly, leading to a build up of fluid and salt.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories